The Indiana University Melvin and Bren Simon Cancer Center is a matrix Cancer Center that organizes and facilitates cancer research, education, patient care, and cancer control and prevention. Our mission is to advance the understanding, prevention and treatment of cancer throughout Indiana and the world with patient centered care, acceleration of promising science and collaborative educational programs. This application seeks funds for the Center's four research programs, six shared facilities, Protocol-Specific Research, Protocol Review and Monitoring System, and Data and Safety Monitoring. In addition, funds are requested for Administration, Program Planning and Evaluation, Developmental Funds, and Senior Leaders. The research programs have been organized and developed to be highly interactive, allowing for successful collaboration among basic, clinical, and population science researchers. The research programs are: 1) Cancer Control, 2) Breast Cancer, 3) Experimental and Developmental Therapeutics, 4) Hematopoiesis, Microenvironment and Immunology. Supporting the members of these programs are six shared resources: Biological Microscopy, Biostatistics and Data Management, Clinical Research Office, Flow Cytometry, Chemical Genomics and Clinical Pharmacology Analytical Analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082709-12S1
Application #
8138717
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1999-09-22
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
12
Fiscal Year
2010
Total Cost
$114,665
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700
Robertson, Michael J; Stamatkin, Christopher W; Pelloso, David et al. (2018) A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother 41:151-157
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10

Showing the most recent 10 out of 256 publications